Compare MBINM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBINM | IMNM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | 663 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | MBINM | IMNM |
|---|---|---|
| Price | $25.07 | $20.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 12.8K | ★ 907.5K |
| Earning Date | N/A | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $863.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.00 | $5.15 |
| 52 Week High | $25.96 | $27.65 |
| Indicator | MBINM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 39.82 |
| Support Level | $24.81 | $18.98 |
| Resistance Level | $25.16 | $22.57 |
| Average True Range (ATR) | 0.19 | 1.12 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 16.72 | 17.98 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.